Evidence map›Paper›PMID 31606826›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2020

Systematic screening using FRAX

C M Parsons, N Harvey, L Shepstone, J A Kanis, E Lenaghan, S Clarke, R Fordham, N Gittoes, I Harvey, R Holland and 9 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

C M ParsonsMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK.
N HarveyMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK.
L ShepstoneUniversity of East Anglia, Norwich, UK.
J A KanisCentre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
E LenaghanUniversity of East Anglia, Norwich, UK.
S ClarkeBristol Medical School, University of Bristol, Bristol, UK.
R FordhamUniversity of East Anglia, Norwich, UK.
N GittoesCentre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital, Birmingham, UK.
I HarveyUniversity of East Anglia, Norwich, UK.
R HollandUniversity of East Anglia, Norwich, UK.
N M RedmondBristol Medical School, University of Bristol, Bristol, UK.
A HoweUniversity of East Anglia, Norwich, UK.
T MarshallUniversity of East Anglia, Norwich, UK.
T J PetersBristol Medical School, University of Bristol, Bristol, UK.
D TorgersonUniversity of York, York, UK.
T W O'NeillArthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
E McCloskeyCentre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
C CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK. cc@mrc.soton.ac.uk.ORCID http://orcid.org/0000-0003-3510-0709
SCOOP Trial Group

Funding

Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

In the large community-based SCOOP trial, systematic fracture risk screening using FRAX

introductionIn the SCreening of Older wOmen for Prevention of fracture (SCOOP) trial, we investigated the effect of the screening intervention on subsequent long-term self-reported adherence to anti-osteoporosis medications (AOM).

methodsSCOOP was a primary care-based UK multicentre trial of screening for fracture risk. A total of 12,483 women (70-85 years) were randomised to either usual NHS care, or assessment using the FRAX

resultsThe mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. Of those participants identified at high fracture risk in the screening group, 38.2% of those on treatment at 6 months were still treated at 60 months, whereas the corresponding figure for the control group was 21.6%. Older age was associated with poorer adherence (OR per year increase in age 0.96 [95% CI 0.93, 0.99], p = 0.01), whereas history of parental hip fracture was associated with greater rate adherence (OR 1.67 [95% CI 1.23, 2.26], p < 0.01).

conclusionsSystematic fracture risk screening using FRAX

Indexed as

Bone DensityDiphosphonatesMedication AdherenceOsteoporosisOsteoporotic FracturesAbsorptiometry, PhotonAgedFemaleHumansInfantMiddle AgedRisk AssessmentRisk FactorsUnited KingdomDiphosphonatesAdherenceEpidemiologyFRAX®MedicationOsteoporosisScreening

Identifiers

PMID31606826
PMCPMC6952271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.